Clik here to view.
Oscar Health's guidance gets a boost from ex-Medicaid members
(This story is from our new Health Tech newsletter. If you’d like to sign up, just click here.) Medicaid’s loss is Oscar Health’s gain. The health insurance upstart is enrolling lots of new members...
View ArticleSarepta faces lower revenue for Duchenne gene therapy ahead of expected sales...
Sarepta Therapeutics recorded lower-than-expected quarterly sales of its gene therapy for Duchene muscular dystrophy, sending the company’s shares down nearly 10% in after hours trading. The biotech...
View ArticleSanofi’s Sarclisa scores in Phase 3 transplant-eligible multiple myeloma test
Sanofi’s Sarclisa added to standard of care has prolonged survival without worsening of disease in a late-stage study in certain multiple myeloma patients, reinforcing the drug’s potential as a...
View ArticleFDA approves Novartis’ complement inhibitor Fabhalta for rare kidney disease
Novartis received accelerated approval from the FDA for a treatment for IgA nephropathy, an autoimmune disease in which too many of an antibody build up in the kidney. The drug, known as iptacopan, is...
View ArticleClik here to view.
UK's NHS, Vertex strike pact, accelerating Casgevy rollout in beta thalassemia
Vertex Pharmaceuticals and NHS England have struck a “landmark” agreement to provide gene therapy Casgevy to beta thalassemia patients, starting with access for up to 460 people. The deal comes as the...
View ArticleClik here to view.
Lilly crushes expectations with GLP-1 franchise, as supply constraints ease
Hopes were high coming into Eli Lilly’s second-quarter earnings results. But they should have been even higher. On Thursday, the Indianapolis drugmaker announced that it was once again upping its...
View ArticleClik here to view.
Entero Therapeutics lays off most staff, pauses R&D to seek strategic...
Just months after Entero Therapeutics completed the merger that brought in its new lead candidate, the debt inherited from the deal is creeping up on the company. Entero abruptly disclosed on Wednesday...
View ArticleClik here to view.
Updated: Recursion to acquire Exscientia to bolster pipeline in one of AI...
Recursion and Exscientia, two longtime bellwethers of AI bio, agreed to merge in an all-stock deal valued at an estimated $688 million. The biotechs’ leaders said they will benefit from combining their...
View ArticleRoivant to 'unveil' pipeline addition next month; Bavarian Nordic gets $156M...
Plus, news about Evotec, Bristol Myers Squibb and Precigen: Roivant hints at another deal: The drugmaker may make an addition to its pipeline, saying it has plans for “unveiling one such program next...
View ArticleQ&A: PhRMA CEO Stephen Ubl on the IRA, challenges to the FDA’s authority and...
As we approach the 2024 presidential election, Stephen Ubl, president and CEO of the pharmaceutical industry’s DC-based trade group PhRMA, said “the political process has really never been more...
View ArticleTIGIT drugs take another hit as Merck stops Phase 3 lung cancer trial for...
Merck is winding down a late-stage test of its anti-TIGIT candidate vibostolimab in small-cell lung cancer after it showed early signs of poor efficacy, in another blow to the TIGIT space. The Phase 3...
View ArticleIntellia’s gene editing therapy succeeds in Phase 2 genetic swelling...
Intellia Therapeutics’ CRISPR-based treatment for a rare genetic disease called hereditary angioedema reduced the bouts of swelling associated with the disease in a mid-stage test, the company...
View ArticleFDA approves Amneal Pharma's extended-release Parkison's treatment
Amneal Pharmaceuticals’ extended-release capsule for Parkinson’s disease has been approved by the FDA following an initial rejection last year. The treatment, which will be marketed as Crexont, is a...
View ArticleApellis and Sobi land another late-stage win for rare kidney disease drug
Empaveli, the kidney disease drug from Apellis Pharmaceuticals and Sobi, reported a Phase 3 trial success that could help the treatment keep pace with a competing therapy from Novartis. On Thursday,...
View ArticleClik here to view.
Lilly’s anti-tau pill for Alzheimer’s fails in Phase 2 study
One month after the long-awaited approval of its first Alzheimer’s drug, Eli Lilly said that another experimental medicine aimed at slowing dementia failed in a Phase 2 study of 330 people. The drug,...
View ArticleClik here to view.
FDA approves Citius Pharma's non-Hodgkin lymphoma drug Lymphir
Citius Pharmaceuticals scored an approval from the FDA on Thursday for its treatment for a rare form of non-Hodgkin lymphoma, bringing to the market a reformulation of a cancer immunotherapy that was...
View ArticleWuXi Biologics gains some traction in Europe in the face of Biosecure threat...
WuXi Biologics appears to be making some progress in Europe in recent days, after securing a new biotech partner and EMA certifications for its manufacturing sites in China. On Thursday, the German...
View ArticleLilly contributes to isotope supplier fundraise; Layoffs at Ajinomoto
Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more. Eli Lilly is injecting some funding into Ionetix for the isotope...
View ArticleClik here to view.
Lilly says to ‘take some caution’ on other companies’ early-stage obesity...
After posting a blowout quarter of financial results, Eli Lilly has almost made the obesity business look easy. But amid investors’ enthusiasm for weight loss drugs, the company’s top scientist warned...
View ArticleAldeyra to resubmit dry eye disease drug this year following positive Phase 3...
Aldeyra Therapeutics plans to make another run at FDA approval for its dry eye disease drug after the agency handed down a complete response letter last year. The company said Thursday that a Phase 3...
View Article